Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Shuttle Pharmaceuticals Holdin - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
SHPH
Nasdaq
2834
https://shuttlepharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Shuttle Pharmaceuticals Holdin
Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on April 4, 2024
- Apr 3rd, 2024 1:00 pm
Presenting on the Emerging Growth Conference 69 Day 2 on April 4 Register Now
- Apr 3rd, 2024 11:00 am
Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update
- Mar 22nd, 2024 1:00 pm
Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on March 6, 2024
- Mar 5th, 2024 2:00 pm
Presenting on the Emerging Growth Conference 68 Day 1 on March 6 Register Now
- Mar 5th, 2024 12:00 pm
Shuttle Pharma Announces Its Intent to Pursue a Rights Offering
- Feb 13th, 2024 1:00 pm
Shuttle Pharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024
- Jan 23rd, 2024 9:30 pm
Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
- Jan 8th, 2024 2:00 pm
Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma
- Dec 11th, 2023 2:00 pm
Presenting on the Emerging Growth Conference 65 Day 2 on December 7th Register Now
- Dec 6th, 2023 12:00 pm
Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on December 7, 2023
- Nov 30th, 2023 2:00 pm
Shuttle Pharmaceuticals Provides Third Quarter 2023 Corporate Update
- Nov 14th, 2023 2:00 pm
Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License Agreement
- Oct 31st, 2023 1:00 pm
Shuttle Pharma to Participate in the Lytham Partners Fall 2023 Investor Conference
- Oct 10th, 2023 1:00 pm
Shuttle Pharma Announces Results of Pre-IND Meeting with FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma
- Sep 25th, 2023 1:00 pm
Shuttle Pharma Participates in Hampton University Proton Therapy Institute Prostate Cancer & Men's Health Fair
- Sep 13th, 2023 1:00 pm
Shuttle Pharma Expands Patent Coverage on HDAC Inhibitor Platform
- Sep 11th, 2023 1:00 pm
Shuttle Pharma's Selective HDAC6 Inhibitor Shown to Stimulate Innate Immune Response in Pre-clinical Studies, as Reported in Molecular Cancer Therapeutics
- Aug 29th, 2023 1:00 pm
Shuttle Pharmaceuticals Provides Second Quarter 2023 Corporate Update
- Aug 15th, 2023 1:00 pm
Shuttle Pharmaceuticals Completes Manufacturing of Active Pharmaceutical Ingredient (API) for Use in Clinical Trial
- Aug 3rd, 2023 1:00 pm
Scroll